KLK13

Across TCGA pan-cancer cohorts, KLK13 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KLK13 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KLK13 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated KLK13 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, KIRC, and SARC are the cancer types where KLK13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	1.000	0.328	.021	16	view →
KIRC	OS	Median	All	0.138	0.655	.021	12	view →
SARC	DFS	Median	All	0.086	0.591	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	II,III,IV	0.111	0.851	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KLK13–BLCA (DFS)

Open the BLCA breakdown →